The Floor Is Shifting Under Mammography. Most Program Leaders Don't Know It Yet.

MammoComply · Richard D. Lippert Jr., President & Founder, Mammologix · Breast Imaging Operations since 1995

Four forces are putting simultaneous pressure on breast imaging programs — a stalled USPSTF, uncertainty about MQSA enforcement, cultural headwinds against organized screening, and the way those three reinforce each other. Here is a plain, nonpartisan account of what is actually happening, what is not, and where to put your attention.

Most breast imaging program leaders don't track federal policy, and that's a perfectly sensible way to run a clinic. Operations are demanding. Regulatory monitoring never feels urgent until the morning something breaks. But the systems that keep women's access to quality mammography standing are under more strain right now than at any point in a decade, and it's the quiet kind — the kind you notice late.

So consider this me pulling you aside for a few minutes. It's policy, not partisanship, and I'll lay it out without taking a side, because the threat to your program doesn't care how you vote. Four forces are in motion at once. Here's each one, what the evidence supports, and where it doesn't.

---

1. The Task Force Hasn't Met in a Year, and the Real Risk Isn't the One You'd Guess

The U.S. Preventive Services Task Force is the independent panel whose recommendations decide which preventive services insurers must cover at no cost, under Section 2713 of the Affordable Care Act.[1] In 2024 it set breast cancer screening at Grade B: biennial screening for average-risk women ages 40 to 74.[2] Under the ACA, a Grade B rating legally bars insurers from charging cost-sharing for covered mammography.[1]

One distinction trips up almost everyone, so let's get it straight. The USPSTF recommendation is the coverage-mandate floor, not the clinical standard. The American College of Radiology, the Society of Breast Imaging, and the American Society of Breast Surgeons all recommend annual screening from age 40, because annual screening delivers the biggest mortality reduction and the most life-years gained.[3][4] Use the coverage language with payers and billing. Use the clinical standard with referring providers and patients.

Now the part worth getting right. The Task Force normally meets three times a year. It hasn't met since March 2025. HHS canceled the July 2025 meeting, the November 2025 meeting fell to the government shutdown, and the March 2026 meeting was postponed a third time.[5] No next date is on the calendar.

Here's where the easy alarm gets it backwards. A panel that doesn't meet also can't change a recommendation, so the favorable 2024 Grade B is still in force, and your patients' no-cost access is, for the moment, protected by the very dysfunction that looks so alarming. The concern worth holding isn't the dormancy. It's what happens if the panel gets reconstituted. A June 2025 Supreme Court ruling confirmed that the HHS Secretary holds supervisory authority over who sits on the panel and may review its recommendations.[6] That same ruling upheld the ACA preventive-services mandate. So the takeaway is narrow and real: coverage is intact today, and its future rests on a panel whose independence is now a matter of policy rather than statute. Watch it. Don't lose sleep over it yet.

---

2. MQSA Isn't Going Anywhere. Its Enforcement Is Worth Watching, Calmly.

Start with the thing people get wrong: MQSA is a statute.[7] The Mammography Quality Standards Act of 1992 can't be erased by executive action, and the requirement that facilities be accredited, certified, and inspected every year is codified law. Survival isn't the question.

Enforcement consistency is. As of October 1, 2024, 8,931 facilities held active MQSA certification, rising to 8,963 by March 2025.[8] Inspecting that many facilities every year takes staffing and budget inside FDA's Center for Devices and Radiological Health. HHS announced FDA workforce reductions in early 2025, and its own fact sheet said device reviewers and inspectors were exempted from the cuts. The support staff around them were not, which can slow the inspection cadence even when the inspectors themselves stay put.[9] That detail cuts against the alarmist read and explains why the issue still deserves a look.

History is the reassuring part here. In the first rounds of MQSA inspections in the mid-1990s, 26% of facilities that had been through two inspection cycles showed significant violations on first evaluation. By the second inspection, that number had dropped to about 10%.[10] The improvement followed the credible, consistent threat of inspection — and it stuck. By early 2025, only 1.2% of inspections turned up a Level 1 violation, the most serious category.[11] Going from roughly one in four facilities with significant violations to about one inspection in eighty flagging the worst kind of finding is what a working enforcement floor produces over thirty years. The risk isn't collapse. It's slow erosion if that credibility ever slips. And the defense is entirely in your hands: treat compliance as continuous, not as an inspection-week scramble. The 2023 Final Rule took effect September 10, 2024 and it's in full force, so personnel-qualification records, breast density notification, and medical outcomes audit standards all want steady attention.[12]

---

3. The Cultural Headwind Is Real. So Is the Counter-Evidence. Hold Both.

There's a strand in today's health-policy talk that frames organized, population-level screening as medical overreach. Mammography isn't its main target right now. That's vaccines, prescribing, and pediatrics. But the intellectual frame is out there, and frames travel.

I'm not going to tell you the underlying science is one-sided, because that's exactly the reflex I'm asking you to distrust. Both of these are true at the same time. The magnitude of overdiagnosis — meaning cancers we detect that would never have gone on to cause harm — is genuinely contested. Estimates swing widely depending on method, and serious researchers land in different places.[13] The American Cancer Society lists overdiagnosis as a possible harm while still recommending screening.[14] And the mortality benefit of organized screening is strong, well-documented, and not seriously in doubt.[15][16]

The mistake skeptics make is letting the unsettled question — how much overdiagnosis — discredit the settled one: that screening saves lives. Those are two different claims, and collapsing them is how a legitimate methodological debate gets weaponized into "maybe skip your mammogram." A woman who hears that message, and who also runs into a new cost-sharing barrier, now has a reasonable-sounding excuse to delay. The mortality cost of delay is documented.[16] That's a behavioral threat, and it calls for a communication response, not a compliance one.

---

4. The Real Problem Is the Way They Feed Each Other — If They Do

On their own, each of these pressures is manageable. The reason to pay attention is the chain they could form — and I want to be careful to call this a risk model, not a forecast. Every link is conditional, not inevitable.

A reconstituted USPSTF could weaken the coverage mandate. A weakened mandate would give insurers room to bring back cost-sharing. Cost-sharing does reduce screening among lower-income patients.[17] A cultural narrative that makes skipping sound reasonable would speed that drop up. Lower volume strains program revenue, strained programs cut infrastructure, and thinner infrastructure raises compliance risk. A facility that reaches that last point during a stretch of uncertain enforcement is in real trouble.

Notice the conditionals, though. The first link isn't active right now, because coverage is intact. The point of mapping the chain isn't to predict doom. It's to see which link to defend first. The programs most exposed are the ones with thin margins, narrow payer mixes, and cost-sensitive patients — which puts rural and safety-net facilities at the most structural risk. No program is completely immune, but most of you have more time than the headlines suggest.

---

What to Do Now

Preparation, not panic. Five things:

Audit against the 2023 Final Rule now, without waiting for an inspection notice. Know exactly where you stand on density notification, personnel-qualification currency, and medical outcomes audit documentation.

Use both screening standards correctly. Coverage-mandate language with payers, and the ACR/SBI/ASBrS annual standard with referrers and patients.

Map your payer exposure. Know which insurers drive your volume, and what a 10 to 15% volume drop would do to your sustainability.

Arm your referring providers with the evidence for annual screening from age 40. Every clinician in your network should be able to make that case to a patient.

Watch the USPSTF actively. A coverage change you learn about months late is volume you've already lost.

---

Across roughly 200 breast imaging programs we support in the eastern, southeastern, and southwestern United States, we track MQSA compliance, medical outcomes auditing, and clinical performance — and from that vantage these pressures line up in ways a single facility rarely gets to see. I'm not asking you to take any of it on faith. The references below are public. Check them. Test what I've argued. And if a line in here made you stop, and then made you wonder who's saying it and why — good. That was the point. The standard of care in breast imaging is worth protecting, and protecting it starts with knowing what's working against it, and what isn't.

---

References

1. Patient Protection and Affordable Care Act. Pub L No. 111-148, § 2713, 42 USC § 300gg-13 (2010).
2. US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930. doi:10.1001/jama.2024.5534
3. Monticciolo DL, Malak SF, Friedewald SM, et al. Breast cancer screening recommendations inclusive of all women at average risk: update from the ACR and Society of Breast Imaging. J Am Coll Radiol. 2021;18(9):1280–1288. doi:10.1016/j.jacr.2021.04.021
4. American Society of Breast Surgeons. Position statement on screening mammography. Approved April 6, 2026.
5. NBC News. Preventive health advisory panel meeting postponed for third time. March 2026. [Corroborated by bipartisan US Senate correspondence, March 24, 2026.]
6. Kennedy v. Braidwood Management, Inc., No. 24-316 (US June 27, 2025).
7. Mammography Quality Standards Act of 1992. Pub L No. 102-539, 42 USC § 263b (1992).
8. US Food and Drug Administration. 2025 Scorecard Statistics (MQSA National Statistics). CDRH. Certified facilities: 8,931 as of October 1, 2024; 8,963 as of March 1, 2025.
9. US Department of Health and Human Services. FDA workforce restructuring fact sheet, 2025 (device reviewers and inspectors exempted; support functions reduced).
10. US General Accounting Office. FDA's Mammography Inspections: While Some Problems Need Attention, Facility Compliance Is Growing. GAO/HEHS-97-25. January 1997.
11. US Food and Drug Administration. 2025 Scorecard Statistics. Level 1 noncompliance 1.2% (FY2025 inspections, as of January 1, 2025).
12. US Food and Drug Administration. Final Rule to Amend the Mammography Quality Standards Act (MQSA); 88 FR 15126. Effective September 10, 2024.
13. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605–613. doi:10.1093/jnci/djq099
14. American Cancer Society. Breast cancer screening guidelines for women at average risk. Revised 2023.
15. Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. J Am Coll Radiol. 2018;15(3 Pt A):408–414. doi:10.1016/j.jacr.2017.11.034
16. Coldman A, Phillips N, Wilson C, et al. Pan-Canadian study of mammography screening and mortality from breast cancer. J Natl Cancer Inst. 2014;106(11):dju261. doi:10.1093/jnci/dju261
17. Wharam JF, Zhang F, Landon BE, Soumerai SB, Ross-Degnan D. Low-socioeconomic-status enrollees in high-deductible plans reduced high-value care. Health Aff. 2013;32(8):1398–1406. doi:10.1377/hlthaff.2012.1027

---

BI-RADS® is a registered trademark of the American College of Radiology, used here for educational purposes only.